Skip to contentI
Indaptus Therapeutics, Inc.
I
INDPIndaptus Therapeutics, Inc. Released Nov 15, 2021, before the open
10-Q filed Nov 15, 2021, 46 days after period end · 0001493152-21-028318
Q3 2021 · 10-Q
Revenue—
Net Income-$3.37M-$3.37MN/M vs Q3 2020N/M vs Q2 2021 EPS Diluted-$0.81-$0.81
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Indaptus Therapeutics, Inc. · CIK 1857044 · Engraved from SEC EDGAR
N/M vs Q2 2021
Operating Income-$3,367,991N/M Operating Cash Flowderived-$5,630,499N/M Free Cash Flowderived-$5,632,153— ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end
9.9% from the close of Nov 12, 2021 to the close of Nov 15, 2021, the first after the release.
before the open$7.49$6.75 Sep 30Nov 15Dec 14